Samy L Habib
Keynote: J Nephrol Ther
D iabetes and cancer represent two complex, diverse, chronic, and potentially fatal diseases. Cancer is the second leading cause of death, while diabetes is the seventh leading cause of death with the latter still likely under reported. There is a growing evidence in recent years suggest substantial increase in cancer incidence in diabetic patients. The worldwide prevalence of diabetes was estimated to rise from 171 million in 2000 to 366 million in 2030. About 26.9% of all people over 65 have diabetes and 60% have cancer. Overall, 8-18% of cancer patients have diabetes. In the context of epidemiology, the burden of both diseases, small association between diabetes and cancer will be clinically relevant and should translate into significant consequences for future health care solutions. Provided recent center retrospective analysis of patients who underwent nephrectomy for renal cell carcinoma (RCC) was performed. Diabetic RCC patients were screened for age, gender, ethnicity, HgA1C, glucose levels and renal function. The data showed that more than of RCC patients with a history of diabetes. The incidence of diabetes in RCC patients was higher in female than male subjects. During diagnosis, the majority of diabetic RCC patients were above 50 years of age. In diabetic RCC cases, clear cell type histology, nuclear grade 2 and tumor size range from 1-5 cm were the most common in each category. Findings indicate that diabetic RCC patients have a predominance of localized, small clear cell RCC. In addition, females with a history of RCC have a higher frequency of diabetes compared to males. This is the first report of clinical and histopathological features of RCC associated with diabetes.
Samy L Habib has completed his PhD at Roswell Park Cancer Center, Buffalo, NY and was trained at University of California, Irvine, University of Texas, Austin, TX and University of Texas Health Science Center, San Antonio, TX. He has published more than 40 papers in reputed journals and serving as an editorial board member and Editor of 10 Journals. He is Associate Professor at UTHSCSA and holds Research Scientist position at the South Texas Veterans Health Care System at Audie Murphy VA Hospital. He was a recipient of several research grant awards from American Diabetes Association, American Heart Association, National Kidney Foundation, New Investigator Award and Merit Review Award from Veterans Affairs, and Pilot Research Award from NIH/NIDDK. He has been a regular member of the Kidney Cancer Study Section of the Medical Research Program, and Tuberous Sclerosis Complex Research Program (TSCRP) study section, Department of Defense
Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report